Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive pulmonary disease (COPD).
The collaboration will focus on testing the usage of the care acceleration solution, the Viz COPD module, which will utilise electronic health record (EHR) data and AI for progressing the identification and management of COPD patients who are at elevated risk.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
COPD, a prevalent and progressive lung condition, causes restricted airflow and troubled breathing.
The module is set to assess EHR data through natural language processing, aligning with established clinical guidelines to screen and triage subjects, and highlighting those at elevated risk for further care and follow-up.
It is built upon the company’s current presence across more than 1,700 health systems and hospitals, engaging more than 60,000 healthcare providers to enhance care and diagnosis in various diseases areas, including respiratory conditions.
The partnership between the three parties is poised to increase patient impact, especially for those who would benefit significantly from enhanced care co-ordination.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataViz.ai co-founder and CEO Chris Mansi stated: “This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care co-ordination across disease areas with critical unmet needs, such as COPD. Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes.
“We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care.”
Viz.ai leverages machine learning and AI algorithms to expedite the diagnosis and care process across numerous hospitals and health systems in Europe and the US.
Viz.ai One, an AI-powered intelligent care co-ordination solution, detects individuals with suspected diseases, supports critical decision-making and aids in improving the outcomes of patients.
Supported by real-world clinical evidence, the solution delivers substantial value to providers, patients, pharma and medical device manufacturers.
